Why the study?
Does hormonal replacement therapy prevent weight gain and central fat redistribution in post-menopausal women?
Does hormonal replacement therapy prevent weight gain and central fat redistribution in post-menopausal women?
Weight gain and central fat redistribution in post-menopausal women are primarily related to aging, while the specific impact of menopause and the preventive role of hormonal replacement therapy remain debated.
Answers are grounded in this paper and cite their sources.
Inconsistent evidence precludes HRT recommendations for weight management; leaves open menopause-specific effects versus aging.
Cardiovascular disease is the leading cause of mortality and morbidity in the post-menopausal woman. The natural menopause does not appear to be an independent risk factor (or a minor one) for coronary heart disease. Obesity, more precisely excessive intra-abdominal fat, is a cardiovascular risk factor especially with regard to the metabolic risk factors associated with this type of obesity. There is a progressive increase in weight gain at the age of menopause but this weight gain is related to ageing independent of whether women are post-menopausal or not, or treated with oestrogens or not. At the same time, there is a central redistribution of fat with a decrease in gluteo--femoral fat and an increase in intra-abdominal fat with an associated muscle mass loss. This trend to central obesity obviously favours an increased cardiovascular risk. With regard to weight gain, these changes in body composition are related to ageing. Different factors (e.g., diet, physical activity, GH secretion, etc.) may be involved. Are these changes related to menopause? Can hormonal replacement therapy prevent them? The results of the studies in this field are not consistent and these questions remain under debate.
No takes yet. Share an insight, caveat, or question.
Colombel et al. (1997) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: